Insider Trading Alert - ENTA, A And BHB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2014, 108 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4.00 to $2,890,477.87.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Mellett Paul J, who is Treasurer and CFO at Enanta Pharmaceuticals, sold 6,000 shares at $47.31 on Dec. 2, 2014. Following this transaction, the Treasurer and CFO owned 126,397 shares meaning that the stake was reduced by 4.53% with the 6,000-share transaction.

Luly Jay R., who is President and CEO at Enanta Pharmaceuticals, sold 15,000 shares at $45.39 on Dec. 2, 2014. Following this transaction, the President and CEO owned 514,338 shares meaning that the stake was reduced by 2.83% with the 15,000-share transaction.

The shares most recently traded at $45.28, down $0.11, or 0.24% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 29,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 69,000

The average volume for Enanta Pharmaceuticals has been 310,900 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $872.3 million and is part of the health care sector and drugs industry. Shares are up 63.05% year-to-date as of the close of trading on Monday.

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. The company has a P/E ratio of 26.1. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Agilent Technologies (A) - FREE Research Report

Sullivan William P, who is Ceo at Agilent Technologies, sold 43,667 shares at $41.83 on Dec. 2, 2014. Following this transaction, the Ceo owned 458,167 shares meaning that the stake was reduced by 8.7% with the 43,667-share transaction.

The shares most recently traded at $41.98, up $0.15, or 0.36% since the insider transaction. Historical insider transactions for Agilent Technologies go as follows:

  • 4-Week # shares sold: 7,682
  • 12-Week # shares sold: 7,682
  • 24-Week # shares sold: 7,682

The average volume for Agilent Technologies has been 3.0 million shares per day over the past 30 days. Agilent Technologies has a market cap of $14.3 billion and is part of the health care sector and health services industry. Shares are down 27.28% year-to-date as of the close of trading on Monday.

Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. The stock currently has a dividend yield of 0.94%. The company has a P/E ratio of 29.1. Currently, there are 5 analysts who rate Agilent Technologies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on A - FREE

TheStreet Quant Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bar Harbor Bankshares (BHB) - FREE Research Report

Toothaker Scott G, who is Director at Bar Harbor Bankshares, bought 126 shares at $30.30 on Dec. 2, 2014. Following this transaction, the Director owned 4,858 shares meaning that the stake was boosted by 2.66% with the 126-share transaction.

The shares most recently traded at $30.35, up $0.05, or 0.16% since the insider transaction. Historical insider transactions for Bar Harbor Bankshares go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 314
  • 12-Week # shares bought: 2,100
  • 12-Week # shares sold: 314
  • 24-Week # shares bought: 3,600
  • 24-Week # shares sold: 314

The average volume for Bar Harbor Bankshares has been 5,400 shares per day over the past 30 days. Bar Harbor Bankshares has a market cap of $181.1 million and is part of the financial sector and banking industry. Shares are up 14.37% year-to-date as of the close of trading on Monday.

Bar Harbor Bankshares operates as the holding company for Bar Harbor Bank & Trust that provides various banking products and services in Maine. The stock currently has a dividend yield of 3.08%. The company has a P/E ratio of 12.2. Currently, there are no analysts who rate Bar Harbor Bankshares a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BHB - FREE

TheStreet Quant Ratings rates Bar Harbor Bankshares as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bar Harbor Bankshares Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers